Poor
Mostly Not Aligned
Patient Risk:
Low
Summary
Most claims concern patent/market dynamics, which are not addressed in the supplied FDA label excerpts; therefore they cannot be validated against the label. One claim is inconsistent with the label in naming/characterization of REPATHA as a treatment for 'high cholesterol and cardiovascular disease' without the label-specific risk-reduction indication and adult/pediatric age indications.
Category Scores
Accurate Statements
Repatha is a biologic product.
Unsupported: the provided FDA label excerpts do not state 'biologic product' or use that term.
Unsupported Statements
Repatha (evolocumab) is an injectable medication used to treat high cholesterol and cardiovascular disease.
Label excerpt specifies specific indications (reduce risk of major adverse CV events in adults at increased risk; adjunct to diet/exercise to reduce LDL-C in hypercholesterolemia, HeFH/HoFH), not a general statement 'treat high cholesterol and cardiovascular disease.'
Repatha is a biologic product with a complex patent landscape.
No patent landscape or 'biologic product' characterization is provided in the supplied label excerpts.
Repatha has patents that are set to expire between 2026 and 2037.
No patent expiration dates are provided in the supplied label excerpts.
The actual expiration date of Repatha patents may differ based on patent disputes or new patents issued.
No patent dispute/new patent dynamics are provided in the supplied label excerpts.
Patent expiration marks the end of pharmaceutical companies' exclusive rights to manufacture and sell medications.
No discussion of patents/exclusive rights is provided in the supplied label excerpts.
Patent expiration can lead to the emergence of generic or biosimilar versions of medications.
No discussion of generics/biosimilars is provided in the supplied label excerpts.
Generic medications often offer lower prices and increased access for patients.
No information regarding pricing/access effects is provided in the supplied label excerpts.
Generic or biosimilar versions of Repatha could lead to lower prices and make the medication more accessible to patients.
No pricing/access effects or market impact statements are provided in the supplied label excerpts.
The exact impact of generic or biosimilar versions of Repatha on prices is uncertain.
No information regarding biosimilar/generic pricing impact is provided in the supplied label excerpts.
Biosimilar versions of Repatha have not yet entered the market.
No statement regarding current market availability of biosimilars is provided in the supplied label excerpts.
Several biosimilar applications for Repatha are underway, pending regulatory approval.
No statements regarding biosimilar application status are provided in the supplied label excerpts.
Contradictions
Important Omissions
Label-specific indication details (adult increased risk for major adverse CV events; adjunct to diet/exercise to reduce LDL-C in hypercholesterolemia, HeFH/HoFH; and pediatric age threshold of 10 years for HeFH/HoFH).
Importance:
Moderate
No dosage/administration information included, despite providing a set of claims about use.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The patent/market claims are not present in the supplied FDA label excerpts and do not directly describe dosing, contraindications, or safety risks. The only label-relevant mismatch is a general/unspecified indication statement that omits the label’s precise indication wording.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Mostly Not Aligned
Primary Issue
Most claims are about patents/biosimilars/pricing and are not supported or discussed in the provided FDA label excerpts; one indication statement is overly general and not aligned to the label’s specific indications.
Suggested Improvement
Restrict label-evaluable claims to the label’s exact indications and age groups (and, if included, any dosing/administration details). Remove or clearly segregate non-label patent/market availability/pricing statements, as they are not contained in the supplied prescribing information.